MBrace

Executive Summary

MBrace Therapeutics is a private, San Diego-based oncology company developing antibody-drug conjugates (ADCs) and targeted antibody therapies. Founded in 2020, the company has raised $85 million to advance its platform centered on novel tumor antigens and optimized linker-payload chemistry. Its goal is to improve the therapeutic index for solid tumors with high unmet need, addressing key limitations of current ADCs such as off-target toxicity and narrow therapeutic windows. With a stage of Phase 1, MBrace is in early clinical development, focusing on lead candidates that target unique epitopes to enhance tumor selectivity. The company's approach leverages proprietary linker technology designed to improve stability and payload release, potentially broadening the efficacy-safety balance. While detailed pipeline disclosures are limited, MBrace's strategy positions it within the competitive ADC landscape, with potential differentiation through its antigen discovery and linker-payload optimization. Execution of early clinical trials and further platform validation will be critical for advancing toward proof-of-concept and attracting additional partnerships or funding.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 Dose-Escalation Data for Lead ADC Candidate40% success
• Q4 2026IND Filing for Second ADC Program60% success
• H2 2026New Partnership or Licensing Deal for Platform35% success